Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CDRI gets approval for Phase III trial of Umifenovir to treat Covid-19

pharmaceutical-technologyJune 22, 2020

Tag: CDRI , Umifenovir , COVID-19 , CSIR

PharmaSources Customer Service